Oncology
Relapsed/refractory Hematological Malignancies
0
Pipeline Programs↗
5
Active Trials↗
5
Companies Involved↗
Relapsed/Refractory Hematological Malignancies is an early-stage landscape with 0 programs across 5 companies. The most active players are Chongqing Precision Biotech Co., Ltd, AstraZeneca, Merck & Co..
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
9
clinical trials
Recruiting4 · 44%
Completed3 · 33%
Unknown status1 · 11%
Not yet recruiting1 · 11%
Clinical Trials
Trial Activity
9 trials
Study of CAR-T Cell Therapy in the Treatment of Relapsed/Refractory Hematological Malignancies
Recruiting·—·Phase 1·NCT05528887·10 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)